Pancreatic cancer

Indexed in Crossref

16 abstracts matching pancreatic cancer from the meeting's journal supplement, fetched live from Crossref 2026-11-12 11:20 UTC. This is a keyword search, not the complete abstract book.

• E16454
  Has early detection improved?: Trends in localized PDAC diagnoses in the U.S. (2004-2022).

  Dina Hauptschein, Paul Kang, Surabhi Amar
• 4229
  Early detection of pancreatic ductal adenocarcinoma (PDAC) with a multiomic liquid biopsy.

  Holly Butler, James Munro Cameron, David Palmer, Alejandro Zulbaran et al.
• E16462
  Evaluation of the impact of GLP-1 receptor agonists (RAs) on stage of PDAC diagnosis: A retrospective matched cohort study.

  Sean O'Connor, Nicholas Seewald, William J. Chapin, Abigail Doucette et al.
• E16384
  Are younger patients considered?: Geographic access and age-focused design in advanced PDAC trials for Appalachian populations.

  Chelsey Mckenna Williams, Chandra Kakarala, Nicole Lisek, Parker Danielson et al.
• 4220
  TME-informed bioprinted 3D tissue model as used to characterize architecture-associated drug uptake and response in PDAC.

  Amr Mahmoud, Brahma Mubarak K. Budhwani, Khidr Kishan K. Budhwani, Naomi R. Jones et al.
• E16410
  A phase I trial of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in metastatic or unresectable pancreatic ductal adenocarcinoma (PDAC).

  Patrick Grierson, Farshid Dayyani, Susanna Varkey Ulahannan, Monica Arun Patel et al.
• 4231
  Safety, efficacy, and immunogenicity of adjuvant therapy with personalized cancer vaccine (PCV) RGL-270 in combination with adebrelimab and mFOLFIRINOX in resectable pancreatic ductal adenocarcinoma (PDAC).

  Si Shi, Jin Xu, Miaoyan Wei, Jialin Li et al.
• 4202
  Proglumide, gemcitabine (GEM), and nab-paclitaxel (NAB-P) in patients (pts) with pancreatic ductal adenocarcinoma (PDAC): Results of the phase 1 PROGEM trial.

  Jill P. Smith, Marcus Smith Noel, Reetu Mukherji, John L. Marshall et al.
• E15104
  Safety and efficacy of daraxonrasib monotherapy as later-line (3L+) treatment for patients (pts) with metastatic pancreatic adenocarcinoma (PDAC).

  Ignacio Garrido-Laguna, Wungki Park, David S. Hong, Meredith Pelster et al.
• 4020
  Multi-modal AI modeling to predict clinical trial outcomes and benchmarks pan-RAS versus KRAS G12D inhibition in KRAS G12D–mutant PDAC.

  Marc Robert de Massy, Jerome Caron, Jean Bouteiller, Anna-Rose Gryspeert et al.
• 4189
  Multicenter phase 2 study of hydroxychloroquine (HCQ) and chlorphenesin carbamate (CPC) in combination with mFOLFIRINOX in patients with advanced pancreatic adenocarcinoma (PDAC).

  Hyehyun Jeong, Choong-kun Lee, So Heun Lee, Kyu-pyo Kim et al.
• 4199
  Precemtabart tocentecan (Precem-TcT, M9140), an anti-CEACAM5 antibody-drug conjugate (ADC), in patients with metastatic pancreatic ductal carcinoma (mPDAC): Results from the phase 1b/2 PROCEADE-PanTumor PDAC substudy.

  Zev A. Wainberg, Francois Ghiringhelli, Hye Jin Choi, Do-Youn Oh et al.
• 4208
  Phase 1/2 study of YL201, an anti-B7H3 antibody–drug conjugate (ADC), in patients with previously treated advanced pancreatic ductal adenocarcinoma (PDAC).

  Liwei Wang, Yanqiao Zhang, Jiujie Cui, Wu Zhuang et al.
• 4193
  Safety and efficacy of nesuparib (JPI-547) with gemcitabine-nab-paclitaxel (GemAbraxane) or modified FOLFIRINOX (mFOLFIRINOX) in patients with locally advanced or metastatic PDAC: Results from an ongoing phase Ib/II study.

  Hye Jin Choi, Joon Oh Park, Jin Won Kim, Choong-kun Lee et al.
• TPS3184
  STELLA: A dose expansion of the ATR kinase inhibitor alnodesertib (ART0380) administered orally in combination with low-dose irinotecan to patients with advanced or metastatic CRC and PDAC.

  Kim Anna Reiss, Babar Bashir, Susanna Varkey Ulahannan, Katrina Sophia Pedersen et al.
• 4204
  Multicentre trial of telemonitored circadian rhythms and electronic patient-reported outcomes (ePROs) for improving tolerability of initial mFOLFIRINOX cycles in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC): MultiDom (NCT04263948).

  Francis Albert Lévi, Claudia Viaro, Ayhan Ulusakarya, Sandrine Dulong et al.